COMP <GO>
ANGO vs TCMD // REVENUE GROWTH (YOY)
AngioDynamics Inc. (NASDAQ) VS. Tactile Systems Technology Inc. (NASDAQ) • 15-METRIC TALLY: ANGO 0
— TCMD 10
▲ REVENUE GROWTH (YOY) LEADER: TCMD
LAST: $11.99 (-2.91%) • MKT CAP: $519.4M
revenue-growth
9.50%
LAST: $23.04 (-5.22%) • MKT CAP: $550.7M
revenue-growth
12.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANGO VS. TCMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANGO | TCMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 75.90% | -21.30 | TCMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.40% | 17.10% | -40.50 | TCMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 14.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.10% | 7.34% | -7.24 | TCMD | /fcf-yield <GO> |
| Operating Margin | -12.50% | 8.90% | -21.40 | TCMD | /operating-margins <GO> |
| Net Profit Margin | -11.50% | 5.80% | -17.30 | TCMD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 9.50% | 12.50% | -3.00 | TCMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.12 | 8.38 | -6.26 | TCMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TCMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 59.2 | -14.70 | TCMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 24.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.4M | $550.7M | -$31.3M | TCMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANGO REV | TCMD REV | ANGO GROSS % | TCMD GROSS % | ANGO FCF | TCMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $320.2M | $329.5M | 54.6% | 75.9% | $508.0K | $40.4M |
| FY 2024 | $292.5M | $293.0M | 53.9% | 74.0% | -$14.6M | $38.3M |
| FY 2023 | $303.9M | $274.4M | — | — | -$28.2M | $35.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANGO // BETA —
TCMD // BETA —